



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

April 2024





© 2024 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
687 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.bccfe.ca
Email: info@bccfe.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to people living with HIV throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART



Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

5. Appendix


- 5.1 Drug Names and Definitions



1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

April 2024

N = 7676



Health Authority	Male	Female	All
FRASER	1577	491	2068
INTERIOR	479	117	596
NORTHERN	162	83	245
VANCOUVER COASTAL	3271	447	3718
VANCOUVER ISLAND	857	170	1027
	6346	1308	7654
	Unknown/not stated:		22
	Total:		7676

Definitions:

On antiretroviral therapy defined as being on treatment in the current month


Unknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male & Female refer to Sex at birth





1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (April 2019 - April 2024)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (April 2019 - April 2024)




Notes:

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month






1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (April 2019 - April 2024)






1.5 BC-CfE Enrolment: New Antiretroviral Participants (April 2019 - April 2024)






1.6 Percent Distribution of Active Participants by CD4 Count (April 2019 - April 2024)






1.7 Percent Distribution of Inactive Participants by CD4 Count
(April 2019 - April 2024)






1.8 Active and Inactive Participants (April 2019 - April 2024)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (April 2019 - April 2024)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (April 2019 - April 2024)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT

(April 2019 - April 2024)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (April 2019 - April 2024)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(April 2019 - April 2024)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (April 2019 - April 2024)






**1.15 Distribution of Participants on Non-Nucleosides
at the time of first start of ARV Therapy by INGREDIENT**

(April 2019 - April 2024)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (April 2019 - April 2024)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first ARV Therapy by INGREDIENT

(April 2019 - April 2024)






1.18 Baseline CD4 for Antiretroviral First Starts
(April 2019 - April 2024)






**1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
(April 2019 - April 2024)**






1.20 Cumulative Resistance Testing Results by Resistance Category (April 2019 - April 2024)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (April 2019 - April 2024)





2.1 Duration of ARV treatment in the Province of BC, 1987-2024 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	33	3	0	3	0		3	<40	3
1988	33	4	0	4	1	510	4	<40	4
1989	31	48	1	49	15	490	45	<40	3
1990	29	48	1	49	23	570	44	<40	3
1991	30	35	3	38	15	490	36	<40	3
1992	30	50	5	55	22	605	53	<40	3
1993	29	107	14	121	61	600	114	<40	3
1994	27	66	8	74	43	570	68	<40	3
1995	27	115	19	134	67	580	124	<40	3
1996	25	293	47	340	177	590	304	<40	3
1997	23	257	28	285	154	560	252	<40	3
1998	23	171	35	206	110	580	179	<40	3
1999	22	143	39	182	106	615	163	<40	3
2000	23	110	26	136	79	620	124	<40	3
2001	22	106	22	128	69	620	121	<40	3
2002	21	112	21	133	73	570	121	<40	3
2003	21	128	26	154	87	550	139	<40	3
2004	19	139	34	173	96	660	154	<40	3
2005	18	167	42	209	124	715	189	<40	3
2006	17	156	40	196	108	660	174	<40	3
2007	17	219	39	258	157	670	235	<40	3
2008	16	254	58	312	191	660	291	<40	3
2009	15	280	61	341	187	650	298	<40	3
2010	13	247	65	312	172	680	276	<40	3
2011	13	297	67	364	204	690	321	<40	3
2012	12	259	63	322	172	705	283	<40	3
2013	11	240	65	305	173	700	274	<40	3
2014	10	259	45	304	163	730	259	<40	3
2015	9	251	39	290	146	724	252	<40	3
2016	8	229	48	277	159	700	241	<40	3
2017	7	192	33	225	135	670	205	<40	3
2018	6	171	44	215	115	760	188	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.1 Duration of ARV treatment in the Province of BC, 1987-2024 (for HIV+ persons currently on treatment)

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Current CD4 Median	Current PVL (n)	Current PVL Median	Current ARV Median
2019	5	213	40	253	158	675	221	<40	3
2020	4	160	51	211	135	730	180	<40	3
2021	3	185	33	218	137	620	200	<40	3
2022	2	244	48	292	196	700	276	<40	3
2023	1	276	71	347	244	580	317	<40	3
2024	0	111	30	141	133	570	137	<40	3
Total:		6345	1311	7656					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2023	7581	793	2051	<40	1320	650
FEB-2023	7521	807	1727	<40	1020	630
MAR-2023	7548	803	1974	<40	1215	640
APR-2023	7553	796	1761	<40	1084	630
MAY-2023	7592	786	1933	<40	1237	650
JUN-2023	7599	787	1841	<40	1097	640
JUL-2023	7577	806	1747	<40	1053	620
AUG-2023	7600	806	1814	<40	1041	630
SEP-2023	7609	797	1775	<40	1064	645
OCT-2023	7611	803	1887	<40	1148	620
NOV-2023	7613	795	1854	<40	1093	650
DEC-2023	7604	801	1549	<40	912	641
JAN-2024	7644	792	1973	<40	1160	650
FEB-2024	7647	784	1773	<40	1016	620
MAR-2024	7638	790	1681	<40	961	650
APR-2024	7676	786	1944	<40	1189	660

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2023	734	276	63	<40	45	550
FEB-2023	787	230	66	<40	53	550
MAR-2023	756	242	78	<40	56	512
APR-2023	760	218	66	<40	47	560
MAY-2023	726	239	65	<40	48	430
JUN-2023	709	201	57	<40	39	460
JUL-2023	740	184	68	<40	50	565
AUG-2023	739	188	63	<40	40	595
SEP-2023	727	207	55	<40	41	540
OCT-2023	736	210	60	<40	46	625
NOV-2023	744	203	65	<40	46	515
DEC-2023	753	192	47	<40	35	473
JAN-2024	709	220	67	<40	49	520
FEB-2024	709	230	58	<40	42	605
MAR-2024	721	201	65	<40	42	605
APR-2024	704	231	66	<40	53	520

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2023	7550	734	20	10	193	143	40	14767
FEB-2023	7505	787	10	11	158	204	-45	14791
MAR-2023	7532	756	15	21	197	176	27	14825
APR-2023	7531	760	13	11	176	169	-1	14854
MAY-2023	7575	726	7	15	205	165	44	14898
JUN-2023	7578	709	14	17	168	165	3	14933
JUL-2023	7556	740	11	11	164	181	-22	14964
AUG-2023	7578	739	11	13	217	192	22	15009
SEP-2023	7579	727	14	5	179	164	1	15029
OCT-2023	7580	736	18	10	170	159	1	15060
NOV-2023	7579	744	17	9	182	172	-1	15096
DEC-2023	7575	753	14	13	169	169	-4	15129
JAN-2024	7615	709	16	11	205	159	40	15161
FEB-2024	7620	709	17	11	181	165	5	15193
MAR-2024	7620	721	12	15	181	183	0	15228
APR-2024	7656	704	17	20	196	163	36	15274

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2023	721	6371	445	44	7581	9.51%	84.04%	5.87%	0.58%	100.00%
FEB-2023	735	6318	429	39	7521	9.77%	84.00%	5.70%	0.52%	100.00%
MAR-2023	750	6312	445	41	7548	9.94%	83.62%	5.90%	0.54%	100.00%
APR-2023	765	6307	440	41	7553	10.13%	83.50%	5.83%	0.54%	100.00%
MAY-2023	802	6314	435	41	7592	10.56%	83.17%	5.73%	0.54%	100.00%
JUN-2023	821	6299	438	41	7599	10.80%	82.89%	5.76%	0.54%	100.00%
JUL-2023	844	6253	440	40	7577	11.14%	82.53%	5.81%	0.53%	100.00%
AUG-2023	866	6240	448	46	7600	11.39%	82.11%	5.89%	0.61%	100.00%
SEP-2023	881	6250	432	46	7609	11.58%	82.14%	5.68%	0.60%	100.00%
OCT-2023	899	6238	433	41	7611	11.81%	81.96%	5.69%	0.54%	100.00%
NOV-2023	920	6211	441	41	7613	12.08%	81.58%	5.79%	0.54%	100.00%
DEC-2023	938	6192	434	40	7604	12.34%	81.43%	5.71%	0.53%	100.00%
JAN-2024	954	6216	432	42	7644	12.48%	81.32%	5.65%	0.55%	100.00%
FEB-2024	974	6198	436	39	7647	12.74%	81.05%	5.70%	0.51%	100.00%
MAR-2024	993	6161	440	44	7638	13.00%	80.66%	5.76%	0.58%	100.00%
APR-2024	1004	6188	438	46	7676	13.08%	80.61%	5.71%	0.60%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	6 17%	2971 40%	1 3%	2147 29%	1 3%	16 0%	23 66%	3491 47%	8 23%	1095 15%	29 83%	4465 60%
FEB-2023	3 13%	2944 40%	1 4%	2097 28%	0 0%	17 0%	18 75%	3502 47%	3 13%	1065 14%	21 88%	4446 60%
MAR-2023	2 6%	2936 40%	2 6%	2071 28%	0 0%	15 0%	27 79%	3551 48%	5 15%	1051 14%	32 94%	4476 60%
APR-2023	3 10%	2948 40%	1 3%	2067 28%	0 0%	15 0%	24 83%	3550 48%	3 10%	1030 14%	26 90%	4469 60%
MAY-2023	10 24%	2940 39%	4 10%	2043 27%	1 2%	16 0%	30 71%	3598 48%	3 7%	1040 14%	32 76%	4513 61%
JUN-2023	4 12%	2934 39%	1 3%	2008 27%	0 0%	14 0%	26 76%	3655 49%	4 12%	1002 13%	30 88%	4533 61%
JUL-2023	5 16%	2917 39%	1 3%	1966 26%	0 0%	14 0%	25 81%	3678 49%	2 6%	985 13%	26 84%	4530 61%
AUG-2023	4 9%	2909 39%	1 2%	1935 26%	0 0%	14 0%	34 76%	3717 50%	9 20%	969 13%	41 91%	4561 61%
SEP-2023	2 10%	2902 39%	1 5%	1910 26%	0 0%	13 0%	15 75%	3746 50%	3 15%	954 13%	18 90%	4578 61%
OCT-2023	2 6%	2905 39%	1 3%	1895 25%	0 0%	14 0%	23 74%	3766 50%	6 19%	936 13%	29 94%	4573 61%
NOV-2023	1 3%	2892 39%	0 0%	1866 25%	0 0%	15 0%	27 77%	3783 51%	7 20%	919 12%	34 97%	4585 61%
DEC-2023	6 18%	2875 39%	4 12%	1831 25%	0 0%	13 0%	25 76%	3820 51%	3 9%	896 12%	27 82%	4595 62%
JAN-2024	9 29%	2881 38%	8 26%	1831 24%	0 0%	13 0%	21 68%	3868 52%	2 6%	890 12%	22 71%	4635 62%
FEB-2024	7 22%	2867 38%	4 13%	1795 24%	0 0%	13 0%	22 69%	3897 52%	3 9%	863 12%	25 78%	4642 62%
MAR-2024	2 6%	2845 38%	0 0%	1760 23%	0 0%	13 0%	30 86%	3929 52%	3 9%	843 11%	33 94%	4658 62%
APR-2024	10 22%	2848 38%	5 11%	1746 23%	0 0%	13 0%	34 74%	3969 53%	3 7%	843 11%	36 78%	4691 62%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	0 0%	339 25%	1 100%	993 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
FEB-2023	0 0%	321 24%	0 0%	953 73%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
MAR-2023	0 0%	317 24%	1 100%	952 73%	0 0%	42 3%	0 0%	1 0%	0 0%	1 0%
APR-2023	0 0%	305 23%	1 100%	957 74%	0 0%	41 3%	0 0%	1 0%	0 0%	1 0%
MAY-2023	0 0%	303 23%	2 100%	951 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUN-2023	0 0%	294 23%	0 0%	936 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUL-2023	0 0%	283 23%	3 100%	927 74%	0 0%	38 3%	0 0%	1 0%	0 0%	1 0%
AUG-2023	0 0%	276 23%	3 100%	914 75%	0 0%	36 3%	0 0%	0 0%	0 0%	0 0%
SEP-2023	0 0%	271 22%	0 0%	909 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
OCT-2023	1 50%	273 23%	1 50%	893 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
NOV-2023	1 33%	260 22%	2 67%	890 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%
DEC-2023	0 0%	248 21%	1 100%	876 76%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
JAN-2024	0 0%	241 21%	3 100%	866 76%	0 0%	33 3%	0 0%	0 0%	0 0%	0 0%
FEB-2024	0 0%	229 21%	0 0%	852 77%	0 0%	31 3%	0 0%	0 0%	0 0%	0 0%
MAR-2024	0 0%	226 21%	1 100%	840 77%	0 0%	30 3%	0 0%	0 0%	0 0%	0 0%
APR-2024	0 0%	225 21%	3 100%	837 77%	0 0%	31 3%	0 0%	0 0%	0 0%	0 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2023	3 43%	192 19%	4 57%	247 25%	0 0%	107 11%	0 0%	255 26%	0 0%	191 19%
FEB-2023	0 0%	202 20%	0 0%	250 25%	0 0%	98 10%	0 0%	249 25%	0 0%	190 19%
MAR-2023	0 0%	209 21%	0 0%	242 25%	0 0%	101 10%	0 0%	246 25%	0 0%	186 19%
APR-2023	1 50%	215 22%	1 50%	232 24%	0 0%	96 10%	0 0%	245 25%	0 0%	187 19%
MAY-2023	1 33%	223 23%	0 0%	232 24%	0 0%	98 10%	0 0%	239 24%	2 67%	187 19%
JUN-2023	0 0%	224 23%	3 75%	228 24%	0 0%	96 10%	0 0%	230 24%	1 25%	180 19%
JUL-2023	0 0%	235 25%	1 100%	222 23%	0 0%	94 10%	0 0%	225 24%	0 0%	178 19%
AUG-2023	0 0%	238 25%	2 100%	222 23%	0 0%	91 10%	0 0%	223 23%	0 0%	182 19%
SEP-2023	0 0%	236 25%	0 0%	218 23%	0 0%	88 9%	1 100%	220 23%	0 0%	177 19%
OCT-2023	0 0%	239 26%	2 100%	216 23%	0 0%	89 10%	0 0%	220 24%	0 0%	173 19%
NOV-2023	0 0%	243 26%	0 0%	209 22%	1 50%	88 9%	0 0%	219 24%	1 50%	173 19%
DEC-2023	1 50%	251 27%	0 0%	205 22%	0 0%	87 9%	0 0%	213 23%	1 50%	176 19%
JAN-2024	0 0%	250 27%	0 0%	200 22%	0 0%	83 9%	0 0%	208 23%	2 100%	181 20%
FEB-2024	0 0%	256 28%	0 0%	192 21%	0 0%	82 9%	0 0%	207 23%	0 0%	182 20%
MAR-2024	0 0%	259 28%	1 100%	190 21%	0 0%	80 9%	0 0%	205 22%	0 0%	181 20%
APR-2024	0 0%	261 29%	0 0%	190 21%	0 0%	82 9%	0 0%	203 22%	0 0%	180 20%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary



**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	bictegravir				cabotegravir				dolutegravir				elvitegravir				fostemsavir				maraviroc				raltegravir			
	Initial		All		Initial		All		Initial		All		Initial		All		Initial		All		Initial		All		Initial		All	
JAN-2023	23	82%	3016	50%	0	0%	0	0%	5	18%	2492	41%	0	0%	269	4%	0	0%	2	0%	0	0%	21	0%	0	0%	302	5%
FEB-2023	18	75%	3040	50%	0	0%	0	0%	6	25%	2476	41%	0	0%	255	4%	0	0%	2	0%	0	0%	21	0%	0	0%	288	5%
MAR-2023	25	74%	3084	51%	0	0%	0	0%	5	15%	2482	41%	2	6%	259	4%	0	0%	2	0%	0	0%	20	0%	2	6%	291	5%
APR-2023	22	81%	3084	50%	0	0%	0	0%	4	15%	2498	41%	1	4%	258	4%	0	0%	2	0%	0	0%	18	0%	0	0%	274	4%
MAY-2023	28	67%	3138	51%	1	2%	3	0%	12	29%	2504	41%	1	2%	250	4%	0	0%	2	0%	0	0%	18	0%	0	0%	278	5%
JUN-2023	26	81%	3197	51%	0	0%	5	0%	6	19%	2509	40%	0	0%	248	4%	0	0%	2	0%	0	0%	18	0%	0	0%	267	4%
JUL-2023	25	83%	3218	52%	0	0%	5	0%	5	17%	2499	40%	0	0%	247	4%	0	0%	2	0%	0	0%	18	0%	0	0%	256	4%
AUG-2023	33	79%	3258	52%	0	0%	7	0%	6	14%	2495	40%	1	2%	245	4%	0	0%	2	0%	0	0%	18	0%	2	5%	253	4%
SEP-2023	15	79%	3289	52%	0	0%	8	0%	4	21%	2500	40%	0	0%	238	4%	0	0%	2	0%	0	0%	18	0%	0	0%	249	4%
OCT-2023	22	76%	3298	52%	0	0%	7	0%	7	24%	2523	40%	0	0%	241	4%	0	0%	2	0%	0	0%	18	0%	0	0%	248	4%
NOV-2023	27	82%	3327	53%	0	0%	9	0%	6	18%	2518	40%	0	0%	233	4%	0	0%	1	0%	0	0%	17	0%	0	0%	244	4%
DEC-2023	24	77%	3365	53%	0	0%	13	0%	7	23%	2506	40%	0	0%	226	4%	0	0%	2	0%	0	0%	16	0%	0	0%	237	4%
JAN-2024	20	65%	3420	53%	1	3%	16	0%	10	32%	2520	39%	0	0%	224	4%	0	0%	2	0%	0	0%	18	0%	0	0%	234	4%
FEB-2024	21	66%	3454	54%	0	0%	15	0%	10	31%	2516	39%	0	0%	219	3%	0	0%	2	0%	0	0%	18	0%	1	3%	231	4%
MAR-2024	30	88%	3499	54%	0	0%	17	0%	4	12%	2501	39%	0	0%	220	3%	0	0%	3	0%	0	0%	17	0%	0	0%	225	3%
APR-2024	34	76%	3545	55%	0	0%	17	0%	11	24%	2502	39%	0	0%	216	3%	0	0%	2	0%	0	0%	18	0%	0	0%	225	3%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Fostemsavir not currently on BC-CfE Formulary





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		3 drugs from 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2023	750	9.89	665	8.77	4728	62.37	718	9.47	649	8.56	71	0.94
FEB-2023	715	9.51	665	8.84	4712	62.65	733	9.75	626	8.32	70	0.93
MAR-2023	699	9.26	653	8.65	4735	62.73	748	9.91	644	8.53	69	0.91
APR-2023	704	9.32	653	8.65	4736	62.70	762	10.09	634	8.39	64	0.85
MAY-2023	706	9.30	644	8.48	4752	62.59	800	10.54	627	8.26	63	0.83
JUN-2023	675	8.88	625	8.22	4788	63.01	819	10.78	627	8.25	65	0.86
JUL-2023	662	8.74	626	8.26	4758	62.80	842	11.11	628	8.29	61	0.81
AUG-2023	643	8.46	621	8.17	4773	62.80	864	11.37	632	8.32	67	0.88
SEP-2023	639	8.40	616	8.10	4793	62.99	879	11.55	617	8.11	65	0.85
OCT-2023	615	8.08	612	8.04	4808	63.17	897	11.79	618	8.12	61	0.80
NOV-2023	611	8.03	600	7.88	4799	63.04	918	12.06	624	8.20	61	0.80
DEC-2023	593	7.80	597	7.85	4808	63.23	936	12.31	614	8.07	56	0.74
JAN-2024	583	7.63	585	7.65	4858	63.55	952	12.45	609	7.97	57	0.75
FEB-2024	564	7.38	585	7.65	4862	63.58	971	12.70	609	7.96	56	0.73
MAR-2024	544	7.12	579	7.58	4848	63.47	991	12.97	618	8.09	58	0.76
APR-2024	539	7.02	570	7.43	4887	63.67	1001	13.04	622	8.10	57	0.74

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month



**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2023	10	2	2	2	2	2	285
FEB-2023	11	2	2	3	1	3	253
MAR-2023	21	0	0	4	3	11	530
APR-2023	11	1	3	1	1	4	325
MAY-2023	15	2	1	2	5	2	374
JUN-2023	17	2	4	3	2	6	340
JUL-2023	11	1	2	3	2	3	260
AUG-2023	13	2	1	4	2	2	255
SEP-2023	5	1	1	0	0	3	616
OCT-2023	10	0	1	3	2	3	390
NOV-2023	9	1	1	0	2	4	575
DEC-2023	13	1	0	3	0	8	592
JAN-2024	11	2	2	2	1	3	287
FEB-2024	11	1	2	4	2	1	281
MAR-2024	15	3	2	1	2	5	440
APR-2024	20	0	4	6	1	9	364

Definitions:**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)**Baseline CD4** is defined as most recent CD4 test before ARV start



2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2023	12448	3803
FEB-2023	12436	3788
MAR-2023	12443	3787
APR-2023	12418	3753
MAY-2023	12426	3731
JUN-2023	12399	3693
JUL-2023	12426	3716
AUG-2023	12423	3698
SEP-2023	12410	3686
OCT-2023	12394	3662
NOV-2023	12381	3649
DEC-2023	12402	3657
JAN-2024	12411	3665
FEB-2024	12424	3672
MAR-2024	12456	3687
APR-2024	12481	3692

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved

Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month






HIV/AIDS Drug Treatment Program


Monthly Report

3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7676
Apr-2024

BY HEALTH SERVICES DELIVERY AREA




BY HEALTH AUTHORITY






3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Apr-2024

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Apr-2024

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Apr-2024

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Apr-2024

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant
Apr-2024

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	6	6	*
	35-49	11	11	*
	50+	31	47	*
	Total HSDA:	48	64	28
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	69	100	50
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	462	625	349
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	230	319	169
Total HA:		809	1108	596

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	6
	20-34	79	80	56
	35-49	188	205	142
	50+	536	817	392
Total HA:		809	1108	596

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	161	224	117
Male	648	884	479

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	596	56	660	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	25	12
	5 years or more	14	7
	<5 years	9	9
	Total HSDA:	48	28
KOOTENAY BOUNDARY	10 years or more	49	34
	5 years or more	11	8
	<5 years	9	8
	Total HSDA:	69	50
OKANAGAN	10 years or more	295	219
	5 years or more	84	63
	<5 years	83	67
	Total HSDA:	462	349
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	141	107
	5 years or more	42	25
	<5 years	47	37
	Total HSDA:	230	169
Total HA:		809	596

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	510	372
	5 years or more	151	103
	<5 years	148	121
Total HA:		809	596

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	54	99	13	30
KOOTENAY BOUNDARY	76	138	19	40
OKANAGAN	240	1076	53	315
THOMPSON/CARIBOO/SHUSWAP	151	579	31	141
Total:	521	1892	116	526

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	130

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	7
	20-34	46	47	35
	35-49	104	108	71
	50+	271	381	198
	Total HSDA:	428	543	311
FRASER NORTH	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	1162	1582	885
FRASER SOUTH	0-19	7	7	7
	20-34	128	131	104
	35-49	306	333	248
	50+	647	994	513
	Total HSDA:	1088	1465	872
Total HA:		2678	3590	2068

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	15	15	15
	20-34	315	320	252
	35-49	769	827	595
	50+	1579	2428	1206
Total HA:		2678	3590	2068

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	641	827	491
Male	2037	2763	1577

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	2068	53	659	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	277	207
	5 years or more	75	41
	<5 years	76	63
	Total HSDA:	428	311
FRASER NORTH	10 years or more	732	537
	5 years or more	221	174
	<5 years	209	174
	Total HSDA:	1162	885
FRASER SOUTH	10 years or more	658	515
	5 years or more	213	164
	<5 years	217	193
	Total HSDA:	1088	872
Total HA:		2678	2068

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1667	1259
	5 years or more	509	379
	<5 years	502	430
Total HA:		2678	2068

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation



4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	152	555	32	63
FRASER NORTH	266	1669	40	236
FRASER SOUTH	232	1872	44	497
Total:	650	4096	116	796

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	208
FRASER NORTH	730
FRASER SOUTH	478
Total:	1416

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth VANCOUVER COASTAL Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	365	541	287
RICHMOND	20-34	27	28	20
	35-49	60	61	49
	50+	126	183	99
	Total HSDA:	213	272	168
VANCOUVER	0-19	9	9	8
	20-34	380	395	284
	35-49	1217	1360	838
	50+	2998	5435	2133
	Total HSDA:	4604	7199	3263
Total HA:		5182	8012	3718

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	13	13	12
	20-34	435	451	321
	35-49	1348	1499	939
	50+	3386	6049	2446
Total HA:		5182	8012	3718

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	575	961	447
Male	4607	7051	3271

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3718	56	660	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	253	202
	5 years or more	55	42
	<5 years	57	43
	Total HSDA:	365	287
RICHMOND	10 years or more	125	97
	5 years or more	31	21
	<5 years	57	50
	Total HSDA:	213	168
VANCOUVER	10 years or more	3283	2271
	5 years or more	718	514
	<5 years	603	478
	Total HSDA:	4604	3263
Total HA:		5182	3718

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	3661	2570
	5 years or more	804	577
	<5 years	717	571
Total HA:		5182	3718

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.9 Distribution of ARV Prescribers in BC-CfE Registries VANCOUVER COASTAL Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	192	417	37	52
RICHMOND	47	326	9	102
VANCOUVER	707	11862	217	5454
Total:	946	12605	263	5608

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	15
RICHMOND	5
VANCOUVER	50
Total:	70

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth VANCOUVER ISLAND Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	366	536	292
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	136	191	110
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	835	1196	625
Total HA:		1337	1923	1027

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	5
	20-34	108	116	75
	35-49	307	346	240
	50+	916	1455	707
Total HA:		1337	1923	1027

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	220	323	170
Male	1117	1600	857

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1027	57	600	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	240	196
	5 years or more	68	46
	<5 years	58	50
	Total HSDA:	366	292
NORTH VANCOUVER ISLAND	10 years or more	98	78
	5 years or more	25	20
	<5 years	13	12
	Total HSDA:	136	110
SOUTH VANCOUVER ISLAND	10 years or more	516	372
	5 years or more	161	122
	<5 years	158	131
	Total HSDA:	835	625
Total HA:		1337	1027

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	854	646
	5 years or more	254	188
	<5 years	229	193
Total HA:		1337	1027

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.12 Distribution of ARV Prescribers in BC-CfE Registries VANCOUVER ISLAND Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	207	942	67	197
NORTH VANCOUVER ISLAND	161	288	35	65
SOUTH VANCOUVER ISLAND	232	1997	41	599
Total:	600	3227	143	861

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	86
NORTH VANCOUVER ISLAND	51
SOUTH VANCOUVER ISLAND	129
Total:	266

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	9	9	8
	35-49	17	20	11
	50+	30	40	15
	Total HSDA:	56	69	34
NORTH WEST	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	75	123	59
NORTHERN INTERIOR	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:	204	306	152
Total HA:		335	498	245

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		335	498	245

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	115	177	83
Male	220	321	162

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	245	53	595	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)



4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration NORTHERN Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	30	*
	5 years or more	8	*
	<5 years	18	*
	Total HSDA:	56	34
NORTH WEST	10 years or more	52	40
	5 years or more	12	9
	<5 years	11	10
	Total HSDA:	75	59
NORTHERN INTERIOR	10 years or more	120	91
	5 years or more	49	33
	<5 years	35	28
	Total HSDA:	204	152
Total HA:		335	245

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	202	146
	5 years or more	69	46
	<5 years	64	53
Total HA:		335	245

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation



4.15 Distribution of ARV Prescribers in BC-CfE Registries NORTHERN Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	39	51	5	7
NORTH WEST	90	169	14	32
NORTHERN INTERIOR	126	514	25	197
Total:	255	734	44	236

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	7
NORTH WEST	22
NORTHERN INTERIOR	21
Total:	50

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Prescriber out of HA is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	12	5
	KOOTENAY BOUNDARY	6	9	5
	OKANAGAN	32	52	19
	THOMPSON/CARIBOO/SHUSWAP	25	54	16
	Total HA:	69	127	45
FRASER	FRASER EAST	36	53	27
	FRASER NORTH	54	98	46
	FRASER SOUTH	80	119	57
	Total HA:	170	270	130
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	27	54	25
	RICHMOND	6	12	5
	VANCOUVER	435	912	351
	Total HA:	468	978	381
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	49	85	38
	NORTH VANCOUVER ISLAND	16	31	12
	SOUTH VANCOUVER ISLAND	49	97	39
	Total HA:	114	213	89
NORTHERN	NORTH EAST	13	17	10
	NORTH WEST	33	69	26
	NORTHERN INTERIOR	71	121	57
	Total HA:	117	207	93
Total:		938	1795	738

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	338	639	270
Male	600	1156	468

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	738	54	550	<40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir: a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Antiretroviral: a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla: the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose of RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

Cabenuva: the ViiV Healthcare trade name for an injectable formulation containing CABOTEGRAVIR and RILPIVIRINE.

Cabotegravir: an INTEGRASE INHIBITOR.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer ("booster") given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Complera: the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

Descovy: the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.





Didanosine (Videx): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir: an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine: a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intence): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fostemsavir: an ATTACHMENT INHIBITOR from ViiV Healthcare. Fostemsavir is a PRODRUG of TEMSAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa: the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine: a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

Maraviroc (Celsentri): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.





MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

N(t)RTI: a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Odefsey: the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix: the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.





Raltegravir (Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant): a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure ("booster").

Stavudine (Zerit): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild: the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq: the ViiV Healthcare's trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir: the ViiV Healthcare's trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada: the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

